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Objectives The aim of this study was to compare the effectiveness of sirolimus-eluting stents (SES) and paclitaxel-eluting
stents (PES) in patients with diabetes mellitus (DM).
Background Drug-eluting stent implantation significantly improved the angiographic and clinical outcomes compared with
bare-metal stent implantation in diabetic patients. However, comparison of SES with PES in diabetic patients
has not been sufficiently evaluated.
Methods This prospective, multicenter, randomized study compared SES (n  200) and PES implantation (n  200) for
diabetic patients (n  400). The primary end point was in-segment restenosis at 6 months according to
intention-to-treat principle.
Results The 2 groups had similar baseline clinical and angiographic characteristics. Six-month in-stent (3.4% vs. 18.2%,
p  0.001) and in-segment restenosis (4.0% vs. 20.8%, p  0.001) and 9-month target lesion revascularization
(2.0% vs. 7.5%, p  0.017) were significantly lower in the SES versus the PES group. The incidence of death (0%
in SES vs. 0.5% in PES, p  0.999) or myocardial infarction (0.5% in SES vs. 0.5% in PES, p  0.999) at
9-month follow-up was not statistically different between the 2 groups. Major adverse cardiac events including
death, myocardial infarction, and target lesion revascularization at 9 months (2.0% vs. 8.0%, p  0.010) were
lower in the SES versus the PES group.
Conclusions Sirolimus-eluting stent implantation is superior in reducing angiographic restenosis and improving 9-month clini-
cal outcomes in patients with DM and coronary artery disease compared with PES implantation. (J Am Coll
Cardiol 2008;52:727–33) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.056(
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tiabetic patients often present unfavorable coronary anat-
my with small and diffusely diseased vessels (1) and exhibit
xaggerated neointimal hyperplasia after bare-metal stent
rom the *Asan Medical Center, University of Ulsan College of Medicine, Seoul,
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Hallym University Sacred Heart Hospital, Anyang, Korea. This study was supported
y the Cardiovascular Research Foundation (Korea), a grant from the Korean
inistry of Health & Welfare as part of the Korea Health 21 Research &
evelopment Project (0412-CR02-0704-0001).(
Manuscript received December 3, 2007; revised manuscript received April 14,
008, accepted April 15, 2008.BMS) implantation compared with nondiabetic subjects
2). Although drug-eluting stent (DES) implantation sig-
ificantly reduced the neointimal hyperplasia and angio-
raphic restenosis compared with BMS in diabetic patients
3), presence of diabetes mellitus (DM) has been still
ssociated with an increased risk of restenosis and unfavor-
ble clinical outcomes in the era of DES (4,5). Recently, the
elative efficacies of sirolimus-eluting stents (SES) and
aclitaxel-eluting stents (PES) in patients with DM have
een evaluated in randomized and registry studies (6–10).
lthough some studies found SES to have greater efficacy
han PES in diabetic patients (9,10), controversy remains
6–8). Therefore, to compare the effectiveness of 2 DES
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DM, we performed a randomized,
multicenter, prospective study
comparing SES and PES in dia-
betic patients (DES-DIABETES
[Drug-Eluting Stent in patients
with DIABETES mellitus] trial).
Methods
Patient selection. This pro-
spective randomized study in-
cluded 400 patients 18 years of
age with angina pectoris and/or a
positive stress test and a native
coronary lesion. The study in-
volved 5 cardiac centers in Korea
between May 2005 and March
2006. Patients were considered
eligible if they had DM, pre-
sented with angina pectoris, or
had a positive stress test and had
clinically significant angiographic
stenosis in a native coronary ves-
sel with a diameter stenosis
50% and visual reference diam-
eter 2.5 mm. Patients were ex-
cluded if they had a contraindi-
ation to aspirin, clopidogrel, or cilostazol; left main disease
diameter stenosis 50% by visual estimate); graft vessel
isease; left ventricular ejection fraction 30%; recent
istory of hematologic disease or leukocyte count 3,000/
m3 and/or platelet count 100,000/mm3; hepatic dys-
unction with asparatate aminotransferase (AST) or alanine
minotransferase (ALT) 3 times the upper normal refer-
nce limit; history of renal dysfunction or serum creatinine
evel 2.0 mg/dl; serious noncardiac comorbid disease with
life expectancy 1 year; planned bifurcation stenting in
he side branch; primary angioplasty for acute myocardial
nfarction (AMI) within 24 h; or inability to follow the
rotocol. In patients with multiple lesions fulfilling the
nclusion and exclusion criteria, the first stented lesion was
onsidered as target lesion. The institutional review board at
ach participating center approved the protocol. All patients
rovided written informed consent.
andomization and procedures. Once the guidewire had
rossed the target lesion, patients were randomly assigned in a
:1 ratio to SES or PES implantation. After DES random-
zation, patients were randomly allocated in a 1:1 ratio to the
riple antiplatelet group (aspirin, clopidogrel, and cilostazol;
riple group; n  200) or the dual antiplatelet therapy group
aspirin and clopidogrel; standard group; n 200) (antiplatelet
rm) on the basis of a 2 2 factorial design with a computer-
enerated randomization sequence. Random assignments were
tratified according to participation sites and blocked with
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
DM  diabetes mellitus
IQR  interquartile range
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimal lumen
diameter
PES  paclitaxel-eluting
stent(s)
QCA  quantitative
coronary angiography
RR  relative risk
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationlock size of 4 or 6 and were distributed in sealed envelopes to oach participating center. The block size was concealed. From
t least 24 h before the procedure and thereafter, all patients
eceived aspirin (200 mg daily) and clopidogrel (loading dose of
00 mg, followed by 75 mg daily for at least 6 months).
atients in the triple group received a loading dose of 200 mg
ilostazol immediately after the procedure and 100 mg twice/
ay for 6 months.
Coronary stenting was performed with the standard
echnique. The decision of pre-dilation or direct stenting
as made by the operator. The use of intravenous glyco-
rotein IIb/IIIa inhibitors was at the operator’s discretion.
12-lead electrocardiogram was obtained after the proce-
ure and before discharge. Serum levels of creatine kinase-
yocardial band isoenzyme were assessed 8, 12, and 24 h
fter the procedure and thereafter if considered necessary.
tudy end point and definitions. The primary end point
f this trial was in-segment restenosis on 6-month
ollow-up study (defined as in-segment stenosis of at least
0%). The secondary end points included 6-month angio-
raphic outcomes such as in-segment late loss and the rate
f in-stent restenosis at 6 months (defined as in-stent
tenosis of at least 50%), stent thrombosis, target vessel
evascularization (TVR), and major adverse cardiac events
MACE) including death, myocardial infarction (MI), and
arget lesion revascularization (TLR).
The diagnosis of DM was considered confirmed in all
atients receiving active treatment with an oral hypoglyce-
ic agent or insulin; for patients with a diagnosis of diabetes
ho were on a dietary therapy alone, enrollment in the trial
equired the documentation of an abnormal blood glucose
evel after an overnight fast. Angiographic success was
efined as in-segment final diameter stenosis 30% by
uantitative coronary angiography (QCA). A Q-wave MI
as defined by the post-procedural presence of new Q waves
f 0.04 s in 2 contiguous leads. Non–Q-wave MI was
efined as a creatine kinase-myocardial band fraction 3
imes the upper limit of normal. Target lesion revascular-
zation was considered clinically driven if prompted by
ymptoms consistent with myocardial ischemia, if preceded
y an abnormal stress test result consistent with myocardial
schemia, if there were other electrocardiographic changes
onsistent with myocardial ischemia, or if the lesion diam-
ter stenosis was more than 70% at follow-up (11). Stent
hrombosis was defined as any of the following after the
rocedure: angiographic documentation of stent occlusion
ith or without the presence of thrombus associated with an
cute ischemic event, unexplained sudden death, or MI not
learly attributable to another coronary lesion (12,13).
ollow-up. Repeat coronary angiography was mandatory
t 6 months after stenting or earlier if indicated by clinical
ymptoms or evidence of myocardial ischemia. Clinical
ollow-up visits were scheduled at 30, 90, 180, and 270 days.
t every visit, physical examination, electrocardiogram,
ardiac events, and angina recurrence were monitored. At each
articipating center, patient data were recorded prospectively
n standard case report forms and gathered in the central data
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August 26, 2008:727–33 DES for Diabetic Patientsanagement center (Asan Medical Center, Seoul, Korea). All
dverse clinical events were adjudicated by an independent
vents committee blinded to the treatment groups.
CA analysis. Coronary angiograms were obtained after
ntracoronary nitroglycerin administration. Procedure
baseline), post-procedure, and follow-up angiograms were
ubmitted to the angiographic core analysis center (Asan
edical Center, Seoul, Korea), in which intraobserver and
nterobserver correlation coefficients were 0.92 and 0.93,
espectively. Digital angiograms were analyzed with an
utomated edge detection system (CASS II, Pie Medical,
aastricht, the Netherlands). The core laboratory was
linded to the treatment assignment. Angiographic vari-
bles included absolute lesion length, stent length, reference
essel diameter, minimal lumen diameter (MLD), percent
iameter stenosis, binary restenosis rate, acute gain, late loss,
nd the patterns of recurrent restenosis. The QCA mea-
urements of target lesions were obtained for both the
tented segment only (in-stent) and the region including the
tented segment as well as the margins 5 mm proximal and
istal to the stent (in-segment). In-segment late loss was
alculated with maximal regional late loss method (14).
atterns of angiographic restenosis were quantitatively as-
essed with the Mehran classification (15).
tatistical analysis. On the basis of results from a previous
tudy (10), we assumed an in-segment angiographic reste-
osis rate of 7% in the SES group and 19% in the PES
roup. With a 2-sided 5% significance level, we estimated
hat 163 patients/group were needed to detect this differ-
nce with a statistical power of 90%. Expecting that approx-
mately 20% of the patients would not return for angio-
raphic follow-up, total sample size was estimated to 400
atients (200 patients/group). Analyses of 2 groups were
erformed according to the intention-to-treat principle.
ontinuous variables are presented as mean  SD or
edian (interquartile range [IQR]) and compared with
tudent unpaired t or Mann-Whitney U tests. Categorical
ariables are presented as numbers or percentages and were
ompared with chi-square or Fisher exact tests. The relative
isk (RR) and its 95% confidence interval (CI) were com-
uted for outcome measures. The Breslow-Day test was
erformed to assess the homogeneity of the RR across
articipating centers and use of cilostazol (16). The adjusted
R and CI after controlling the center and use of cilostazol
ere computed by the Mantel-Haenszel method. For the
rimary outcome, we also calculated the absolute difference
etween SES and PES patients with and without cilostazol.
p value 0.05 was considered to indicate a significant
ifference. All statistical analyses were performed with SAS
ersion 9.1 (SAS Institute, Cary, North Carolina).
esults
aseline characteristics of the patients. Table 1 shows the
aseline clinical characteristics of the study groups. There (ere no significant differences between the 2 groups in
aseline clinical characteristics and risk factors.
rocedural results and in-hospital outcomes. Table 2
hows angiographic characteristics and procedural results.
he 2 groups have similar anatomical and procedural
haracteristics. All stents were successfully implanted, and
he angiographic success rate was 99.5% in all groups. The
groups were treated with similar stented lengths and
umber of implanted stents/target lesion. Procedure-related
on–Q-wave MI occurred similarly in both arms. Acute
tent thrombosis developed in 1 patient (0.5%) treated with
ES during hospital stay. In-hospital events, including
-wave MI, emergency bypass surgery, or death, did not
ccur in either group.
ngiographic outcomes. Baseline and post-procedural
CA outcomes for study groups are shown in Table 3. The
groups had similar baseline and post-procedural QCA
haracteristics, except for higher maximal inflation pressure
n the SES group versus the PES group.
Follow-up angiography was performed in 330 patients
82.5%)—176 (88%) SES and 154 (77%) PES patients. The
edian duration of angiographic follow-up was similar in
he 2 groups (187 [IQR: 178 to 201] and 188 [IQR: 178 to
03] days for the SES and PES groups, respectively, p 
.762). Results of QCA measurements at follow-up are
hown in Table 3. The in-stent and -segment late loss were
ignificantly lower in the SES versus in the PES group.
ollow-up in-stent and -segment MLD also were signifi-
antly larger in SES versus in PES. In-segment restenosis,
he pre-specified primary end point, was identified in 7
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Variable
SES
(n  200)
PES
(n  200) p Value
Age, yrs 61.1 8.9 60.7 8.8 0.622
Men 122 (61.0%) 110 (55.0%) 0.224
Hypertension 114 (57.0%) 124 (62.0%) 0.308
Treatment of diabetes
mellitus
0.972
Dietary therapy alone 18 (9.0%) 19 (9.5%)
Oral hypoglycemic agent 150 (75.0%) 148 (74.0%)
Insulin 32 (16.0%) 33 (16.5%)
Glycosylated hemoglobin, % 7.7 1.8 7.8 1.6 0.682
Total cholesterol 200 mg/dl 55 (27.5%) 63 (31.5%) 0.380
Current smoker 54 (27.0%) 57 (28.5%) 0.738
Previous PCI 25 (12.5%) 25 (12.5%) 0.999
Previous CABG 4 (2.0%) 3 (1.5%) 0.999
Clinical diagnosis 0.098
Stable angina 86 (43.0%) 82 (41.0%)
Unstable angina 80 (40.0%) 67 (33.5%)
Acute myocardial infarction 34 (17.0%) 51 (25.5%)
Left ventricular ejection
fraction, %
59 10 58 10 0.370
Multivessel disease 119 (59.5%) 137 (68.5%) 0.170
ABG  coronary artery bypass surgery; PCI  percutaneous coronary intervention; PES 
aclitaxel-eluting stent; SES  sirolimus-eluting stent.4.0%) SES and 32 (20.8%) PES patients (RR: 0.19; 95%
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DES for Diabetic Patients August 26, 2008:727–33I: 0.09 to 0.42; p  0.001). In-stent restenosis rate was
lso lower in the SES than in the PES group (3.4% vs.
8.2%; RR: 0.19; 95% CI: 0.08 to 0.44; p  0.001). The
est for assessing the homogeneity of the RR across the
enter and use of cilostazol were not significant for in-
egment (Breslow-Day test, p  0.317) and in-stent reste-
Angiographic Characteristics and Procedural Re
Table 2 Angiographic Characteristics and P
Variable
Target vessel
Left anterior descending artery
Left circumflex artery
Right coronary artery
Procedure-related non–Q-wave MI
Maximal inflation pressure, atm
Use of intravascular ultrasound
Use of glycoprotein IIb/IIIa inhibitor
Pre-dilation before stenting
Post-stenting adjunctive balloon dilation
Largest balloon size for adjunctive dilation, mm
Multivessel stenting
Number of used stents at the target lesion
MI  myocardial infarction; other abbreviations as in Table 1.
uantitative Angiographic Measurements
Table 3 Quantitative Angiographic Measurements
Variable
SES
(n  200)
PES
(n  200) p Value
Reference diameter, mm 2.80 0.43 2.80 0.43 0.962
Lesion length, mm 25.8 12.9 27.2 14.2 0.338
Stented length, mm 32.5 13.9 33.2 15.2 0.665
Minimal lumen diameter, mm
In-segment
Before procedure 0.79 0.50 0.73 0.46 0.236
After procedure 2.23 0.46 2.27 0.47 0.392
At follow-up 2.24 0.50 1.93 0.60 0.001
In-stent
After procedure 2.55 0.46 2.57 0.41 0.559
At follow-up 2.44 0.51 2.01 0.67 0.001
Diameter stenosis, %
In-segment
Before procedure 68.1 14.7 69.4 12.7 0.423
After procedure 20.2 12.1 19.2 10.3 0.379
At follow-up 21.3 12.5 31.6 18.2 0.001
In-stent
After procedure 10.5 11.5 8.9 11.6 0.230
At follow-up 14.1 15.2 26.3 22.0 0.001
Acute gain, mm
In-segment 1.43 0.60 1.53 0.59 0.119
In-stent 1.76 0.60 1.84 0.57 0.171
Late loss, mm
In-segment 0.31 0.40 0.67 0.53 0.001
In-stent 0.13 0.43 0.53 0.57 0.001
Binary angiographic restenosis
In-segment 7 (4.0%) 32 (20.8%) 0.001
In-stent 6 (3.4%) 28 (18.2%) 0.001bbreviations as in Table 1.osis (Breslow-Day test, p  0.246). Although there was
nteraction between types of DES and use of cilostazol in
elative measure (p  0.001 for in-segment restenosis),
bsolute measure was not statistically significant (p 
.861). This phenomenon was due to 0% in-segment
estenosis of the SES  cilostazol group. With regard to
n-segment restenosis, the pre-specified primary end point,
bsolute difference was 8% in SES patients and 6.8% in
ES patients, according to use of the cilostazol (p  0.861)
Fig. 1).
In patients with restenoses, a pattern of focal restenosis
type I) was more common in the SES than in the PES
roup (Table 4).
linical outcomes. A minimum 9-month clinical
ollow-up was performed in all patients. One cardiac death
ccurred in PES patients due to nontarget vessel MI.
ural Results
SES
 200)
PES
(n  200) p Value
0.707
(61.0%) 118 (59.0)
(14.0%) 25 (12.5%)
(25.0%) 57 (28.5%)
(8.0%) 18 (9.0%) 0.720
4 3.6 14.6 3.6 0.028
(33.5%) 64 (32.0%) 0.749
(5.5%) 7 (3.5%) 0.470
(97.0%) 190 (95.0%) 0.445
(48.5%) 87 (43.5%) 0.316
8 0.43 3.25 0.42 0.104
(32.0%) 69 (34.5%) 0.596
8 0.49 1.28 0.56 0.936
Figure 1 The In-Segment Restenosis Rate According
to Drug-Eluting Stent and Use of Cilostazol
There is interaction between the type of drug-eluting stent and use of cilostazol
for in-segment restenosis (p  0.001). Although there was significant differ-
ence in relative measure of in-segment restenosis rate due to 0% in-segment
restenosis rate of the sirolimus-eluting stent  cilostazol group, the absolute
measure was not statistically different (p  0.861).sults
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August 26, 2008:727–33 DES for Diabetic Patientsyocardial infarction occurred in 1 patient/group. During 9
onths, only 1 stent thrombosis occurred in the SES
atients, which was angiographically documented at 6 h
fter index procedure. The patient was successfully treated
ith repeat intervention (Table 5).
The rates of TLR (2.0% vs. 7.5%; RR: 0.27; 95% CI: 0.09
o 0.79; p  0.017) and TVR (3.5% vs. 8.0%, p  0.053)
ere lower in the SES than in the PES group. Clinically
riven TLR (1.5% vs. 6.0%, p  0.032) and TVR (2.0% vs.
.5%, p  0.017) rates were also lower in the SES than in
he PES group. At 9 months, MACE was lower in the SES
han in the PES group (2.0% vs. 8.0%; RR: 0.25; 95% CI:
.09 to 0.73; p  0.010). The composite of death, MI, or
VR was also significantly lower in the SES than in the
ES patients (3.5% vs. 8.5%, p  0.035).
iscussion
he major finding of this study is that SES implantation is
ssociated with reduction of late loss and 6-month angio-
raphic restenosis, relative to PES implantation, which is
ranslated to reduction of subsequent TLR and MACE
ith no difference of death or MI in patients with DM.
Drug-eluting stents significantly reduced angiographic
estenosis and cardiac events compared with BMS in
atients with DM (3). The presence of DM is associated
ith higher neointimal hyperplasia, restenosis, and unfavor-
ble clinical outcomes in the era of DES (17,18). Recently,
everal randomized trials and registries showed inconsistent
esults regarding the superiority of SES over PES in diabetic
atients (6–10). The current study shows that SES are more
ffective than PES in reducing angiographic restenosis and
ubsequent clinical outcomes.
In the current study, the in-stent (0.13  0.43 mm vs.
.53  0.57 mm, p  0.001) and in-segment late loss
0.31  0.40 mm vs. 0.67  0.53 mm, p  0.001) were
ignificantly lower in the SES than in the PES group.
lthough in previous studies, the late loss of the SES group
in-stent: 0.09  0.4 mm to 0.26  0.40 mm; in-segment:
.41  0.6 mm to 0.43  0.45 mm) and the PES group
ngiographic Patterns of Restenosis
Table 4 Angiographic Patterns of Restenosis
Variable
SES
(n  7)
PES
(n  32) p Value
Focal 6 (85.7%) 18 (56.3%) 0.216
IA (articulation or gap) 0 0
IB (margin) 1 5
IC (focal body) 4 8
ID (multifocal) 1 5
Diffuse 1 (14.3%) 14 (43.8%) 0.216
II (intrastent) 1 10
III (proliferative) 0 3
IV (total occlusion) 0 1
Length of restenosis 7.56 5.21 15.5 10.9 0.091
lassified with the Mehran criteria (15).
Abbreviations as in Table 1.in-stent: 0.46  0.64 mm to 0.50  0.6 mm; in-segment:
M
l.67 0.62 mm to 0.68 0.6 mm) had somewhat different
esults than our study due to study design, enrolled patient/
esion characteristics, and stenting procedures (3,9,19,20),
he 2 randomized studies comparing SES and PES in
iabetic patients showed that the SES group had signifi-
antly reduced late loss compared with the PES group
9,20), which was a finding consistent with that of our
tudy.
We also found that SES reduced in-segment restenosis
4.0% vs. 20.8%, p  0.001), the pre-specified primary end
oint, by 81% (relative reduction) compared with PES.
revious registry data comparing SES and PES also showed
restenosis rate similar to those of our study (5.3% in SES
nd 23.1% in PES, p  0.01) (10). However, this relative
eduction is greater than those reported in previous random-
zed studies of various lesion subsets that showed a 7% to
7.2% relative reduction (9,21–23). The current study
nvolved diabetic patients with a relatively long diseased
egment, which might have contributed to the more pro-
ounced differences between the 2 stents. According to
revious randomized trials comparing SES versus PES, SES
howed a more profound benefit over PES in more complex
atients/lesions (9,22,23)—such as diabetic patients, in-
tent restenosis, and long lesions—than in trials involving
elatively simple lesions (11,24). The restenosis rate of
SAR-DIABETES (The Intracoronary Stenting and An-
iographic Results: Do Diabetic Patients Derive Similar
enefit from Paclitaxel-Eluting and Sirolimus-Eluting
tents) (9), a randomized study comparing SES and PES in
iabetic patients, was 6.9% in SES and 16.5% in PES
atients. Our study had longer lesion length (25.8 mm of
ES and 27.2 mm of PES) than those of ISAR-
IABETES (12.4 mm of SES and 13.4 mm of PES),
linical Outcomes at 9 Months
Table 5 Clinical Outcomes at 9 Months
Variable
SES
(n  200)
PES
(n  200) p Value
Death 0 1 (0.5%) 0.999
Cardiac 0 1 (0.5%)
Noncardiac 0 0
MI 1 (0.5%) 1 (0.5%) 0.999
Q-wave 0 1 (0.5%)
Non–Q-wave 1 (0.5%) 0
TLR 4 (2.0%) 15 (7.5%) 0.017
Drug-eluting stent 1 (0.5%) 10 (5%)
Cutting 1 (1%) 3 (1.5%)
Bypass surgery 2 (1%) 2 (1%)
Stent thrombosis 1 (0.5%) 0 0.999
Acute 1 (0.5%) 0
Subacute 0 0
Late 0 0
TVR 7 (3.5%) 16 (8.0%) 0.053
Death/MI/TVR 7 (3.5%) 17 (8.5%) 0.035
MACE (death/MI/TLR) 4 (2.0%) 16 (8.0%) 0.010ACE  major adverse cardiac events; MI  myocardial infarction; TLR  target lesion revascu-
arization; TVR  target vessel revascularization; other abbreviations as in Table 1.
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ver PES in our study.
Due to the reduced risk of angiographic restenosis, the
ubsequent TLR (2.0% vs. 7.5%; RR: 0.27; 95% CI: 0.09 to
.79; p  0.017) was significantly reduced in SES patients
ompared with PES patients. These results were also found
n a recent meta-analysis comparing SES and PES in a
ariety of clinical settings and lesion complexity, in which
ES significantly reduced the risk of reintervention (25). In
ur study, death or MI was similar in the 2 groups.
onsequently, MACE including death, MI, and TLR was
ignificantly lower in SES than in PES patients, mainly
riven by TLR (2.0% vs. 8.0%, p  0.010).
Diabetes mellitus has been reported to be associated with
ntiplatelet resistances (26). This is explained by aggressive
therosclerosis, abnormal endothelial function, impaired fibri-
olysis, and platelet hyperactivity after arterial injury. Impor-
antly, increased platelet activity is considered critically involved
n the increased thrombogenic potential among diabetic pa-
ients. These findings might be associated with an increased
isk of stent thrombosis after coronary stenting, which has been
eported in previous registry data of DES (27). Furthermore, a
ecent meta-analysis showed that the PES had an increased
isk of stent thrombosis compared with SES during a mean
ollow-up period ranging from 9 to 37 months (25). However,
n our study, stent thrombosis occurred in only 1 patient
eceiving SES during 9 months. Thus, to evaluate the impact
f DM on stent thrombosis after DES implantation, a larger
opulation study would be required.
tudy limitations. The present study has several limita-
ions. First, our use of routine 6-month angiography might
ave resulted in an underestimation of the rates of restenosis
nd TLR compared with a study with a longer angiographic
ollow-up period. Second, there might be possible bias
ssociated with clinical decisions related to TLR by opera-
ors, but this limitation has mostly been compensated for by
schemic-driven TLR. Third, the rate of angiographic
ollow-up was nonuniform in both groups.
onclusions
he present study showed that SES implantation re-
ulted in a significantly reduced risk of 6-month angio-
raphic restenosis and 9-month TLR or MACE without
significant difference in MI or death compared with
ES implantation.
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